2013 Fiscal Year Final Research Report

Translational Research for cobinational chemotherapy with tumor microcirculation promotional agent in patients with advanced non-small cell lung cancer

Research Project

Project/Area Number	23591133
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Multi-year Fund
Section	一般
Research Field	Respiratory organ internal medicine
Research Institution	Tohoku University
Principal Investigator	YASUDA Hiroyasu 東北大学, 大学院医学系研究科, 非常勤講師 (90396482)
Project Period (FY)	2011 – 2013
Keywords	一酸化窒素供与剤 / 抗癌剤感受性 / 腫瘍直接浸潤 / 低酸素誘導因子 / 腫瘍組織内低酸素状態 / 無作為化比較試験 / ニトログリセリン / 非小細胞肺癌
Research Abstract	Nitoroglycerin (NTG), nitric oxide donating agent (NDA), significantly reduced distribution of hypoxic area in solid cancer tissue in tumor bearing model mice. We made tumor bearing model mice with murine adenocarcinoma LLC cells and performed chemotherapy with them. Tumor growth curve was significantly inhibited in the group treated with pemetrexed and NTG compared with the group treated with pemetrexed alone. Multicenter-phase II trial of 3rd line chemotherapy with amrubicin with NTG patch in patients with stage IIIB and IV non-small cell lung cancer was performed in Kyoto Univ., Tohoku Univ., Shinshu Univ., and Juntendo Univ. Now the data analysis has been performed, and will be published.